Top

Published in:

Open Access 01-03-2014 | Research Article

Vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 13 case–control studies

Authors: Yulan Yan, Hongjie Liang, Taijie Li, Shihui Guo, Meng Li, Shan Li, Xue Qin

Published in: Tumor Biology | Issue 3/2014

Abstract

The association between vascular endothelial growth factor (VEGF) +936C/T polymorphism and breast cancer risk has been widely reported, but results were inconsistent. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Eligible articles were identified through search of databases including PubMed, Embase, and Chinese Biomedical Literature Database (CBM). The association between the VEGF +936C/T polymorphism and breast cancer risk was conducted by odds ratios (ORs) and 95 % confidence intervals (95 % CIs). Finally, a total of 13 studies with 6,879 cases and 7,219 controls were included in our meta-analysis. Overall, a significant association was found between VEGF +936C/T polymorphisms and the risk of breast cancer in overall populations under five models (T vs. C: OR = 0.83, 95 % CI = 0.73–0.94, P = 0.002; TT vs. CC: OR = 0.74, 95 % CI = 0.61–0.91, P = 0.004, Fig. 1a; TC vs. CC: OR = 0.83, 95 % CI = 0.71–0.96, P = 0.014; TT vs. CC/CT: OR = 0.77, 95 % CI = 0.62–0.94, P = 0.010; TT/TC vs. CC: OR = 0.82, 95 % CI = 0.72–0.95, P = 0.006). In the subgroup analysis by ethnicity, there were also significant associations found between VEGF +936C/T polymorphism and breast cancer risk in Asians and Caucasians. In conclusion, the results of our meta-analysis suggest that the VEGF +936C/T polymorphism is significantly associated with breast cancer development and the VEGF 936T allele carriers may be associated with decreased breast cancer risk.

Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6:229–39.PubMedCentralPubMedCrossRef

Sturgeon SR, Schairer C, Grauman D, El Ghormli L, Devesa S. Trends in breast cancer mortality rates by region of the United States, 1950–1999. Cancer Causes Control. 2004;15:987–95.PubMedCrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef

Meteoglu I, Dikicioglu E, Erkus M, Culhaci N, Kacar F, Ozkara E, et al. Breast carcinogenesis. Transition from hyperplasia to invasive lesions. Saudi Med J. 2005;26:1889–96.PubMed

Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–40.PubMed

O’Brien JM. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland, by P. Lichtenstein, N.V. Holm, P.K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, and K. Hemminki. N Engl J Med 343:78–84, 2000. Surv Ophthalmol 2000;45:167–168.

Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.PubMedCrossRef

Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med. 2001;7:552–6.PubMedCrossRef

Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet. 2003;33(Suppl):238–44.PubMedCrossRef

10.

Hu Z, Li X, Yuan R, Ring BZ, Su L. Three common tp53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat. 2010;120:705–14.PubMedCrossRef

11.

Qiu LX, Yao L, Zhang J, Zhu XD, Zhao XM, Xue K, et al. Xpd lys751gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects. Breast Cancer Res Treat. 2010;124:229–35.PubMedCrossRef

12.

Ferrara N. Vegf and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803.PubMedCrossRef

13.

Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812–6.PubMed

14.

Chae YS, Kim JG, Sohn SK, Cho YY, Moon JH, Bae HI, et al. Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology. 2006;71:266–72.PubMedCrossRef

15.

Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog. 2009;48:563–9.PubMedCrossRef

16.

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 c/t mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37:443–8.PubMedCrossRef

17.

Qiu LX, Wang K, Yang S, Mao C, Zhao L, Yao L, et al. Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility. Mol Biol Rep. 2011;38:4491–4.PubMedCrossRef

18.

Wolf G, Aigner RM, Schaffler G, Langsenlehner U, Renner W, Samonigg H, et al. The 936c > t polymorphism of the gene for vascular endothelial growth factor is associated with ¹⁸F-fluorodeoxyglucose uptake. Breast Cancer Res Treat. 2004;88:205–8.PubMedCrossRef

19.

Luo T, Chen L, He P, Hu QC, Zhong XR, Sun Y, et al. Vascular endothelial growth factor (vegf) gene polymorphisms and breast cancer risk in a chinese population. Asian Pac J Cancer Prev. 2013;14:2433–7.PubMedCrossRef

20.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. The single-nucleotide polymorphisms +936 c/t vegf and −710 c/t vegfr1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat. 2012;133:769–78.PubMedCrossRef

21.

Absenger G, Szkandera J, Stotz M, Pichler M, Winder T, Langsenlehner T, et al. A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog 2013

22.

Oliveira C, Lourenco GJ, Silva PM, Cardoso-Filho C, Favarelli MH, Goncales NS, et al. Polymorphisms in the 5′- and 3′-untranslated region of the vegf gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumour Biol. 2011;32:295–300.PubMedCrossRef

23.

Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, et al. The VEGF_936_C > T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett. 2008;262:71–6.PubMedCrossRef

24.

Balasubramanian SP, Cox A, Cross SS, Higham SE, Brown NJ, Reed MW. Influence of vegf-a gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007;121:1009–16.PubMedCrossRef

25.

Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, et al. Population-based case–control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev. 2006;15:1148–52.PubMedCrossRef

26.

Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006;8:R22.PubMedCentralPubMedCrossRef

27.

Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11:3647–53.PubMedCrossRef

28.

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 c/t gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003;106:468–71.PubMedCrossRef

29.

Lin GT, Tseng HF, Yang CH, Hou MF, Chuang LY, Tai HT, et al. Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS. 2009;13:165–72.PubMedCrossRef

30.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef

31.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

32.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

33.

Zamora-Ros R, Rothwell JA, Scalbert A, Knaze V, Romieu I, Slimani N, et al. Dietary intakes and food sources of phenolic acids in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Nutr 2013:1–12.

34.

Tobias A, Campbell MJ. Modelling influenza epidemics in the relation between black smoke and total mortality. A sensitivity analysis. J Epidemiol Community Health. 1999;53:583–4.PubMedCentralPubMedCrossRef

35.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralPubMedCrossRef

36.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef

37.

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.PubMedCrossRef

38.

Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611.PubMedCrossRef

39.

Hu YF, Luscher B, Admon A, Mermod N, Tjian R. Transcription factor ap-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev. 1990;4:1741–52.PubMedCrossRef

40.

Mermod N, Williams TJ, Tjian R. Enhancer binding factors ap-4 and ap-1 act in concert to activate sv40 late transcription in vitro. Nature. 1988;332:557–61.PubMedCrossRef

41.

Yang DS, Park KH, Woo OH, Woo SU, Kim AR, Lee ES, et al. Association of a vascular endothelial growth factor gene 936 c/t polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011;125:849–53.PubMedCrossRef

Title: Vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 13 case–control studies
Authors: Yulan Yan
Hongjie Liang
Taijie Li
Shihui Guo
Meng Li
Shan Li
Xue Qin
Publication date: 01-03-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1354-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma

Haplotype analysis of RECQL5 gene and laryngeal cancer

Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma

The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer

Part I—mechanism of adaptation: high nitric oxide adapted A549 cells show enhanced DNA damage response and activation of antiapoptotic pathways

Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population

Keynote webinar | Spotlight on antibody–drug conjugates in cancer